Clinical Trials on Zika Virus Disease in Belgium

Total 11218 results

Universitaire Ziekenhuizen KU Leuven

Recruiting

In-depth Immunological Investigation of COVID-19. (COntAGIouS)

Coronavirus Infections

Belgium
Tilman S.A.
Artialis

Completed

Covid-19, Hospitalized, PatIents, Nasafytol

Coronavirus Infection

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Hepatitis A

Belgium
Erasme University Hospital

Completed

sgp130 in Chronic Human Liver Disease

Chronic Hepatitis C Virus Infection | Alcoholic Liver Disease

Belgium
Institute of Tropical Medicine, Belgium

Withdrawn

RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection (CHIK_urine)

Chikungunya Fever

Belgium, Aruba
Jessa Hospital

Completed

Borderline COVID-19 PCR Test Result

Covid19 | Virus

Belgium
Hasselt University

Completed

Hepatitis B Virus Prevalence and Risk Factors in Belgium (HBVBE)

Hepatitis B

Belgium
Hasselt University

Unknown

Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg (HBVTR)

Hepatitis B

Belgium
Erasme University Hospital
Roche Diagnostics; LHUB-ULB

Terminated

Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room

RSV Infection | Influenza Viral Infections

Belgium
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Sciensano
Institute of Tropical Medicine, Belgium; Université Libre de Bruxelles; Mensura...

Completed

Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV)

COVID-19 | Influenza, Human | SARS Virus | Espiratory Tract Infections

Belgium
LiteVax BV
University Hospital, Ghent

Completed

Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin (TETRALITE-I)

Influenza

Belgium
Vaccitech (UK) Limited

Completed

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Influenza

Belgium
GlaxoSmithKline

Completed

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Influenza

Belgium
Cyril Barbezange
Sciensano; Belgian Federal Public Service, Food Chain Safety and Environment; Agentschap Zorg en Gezondheid

Enrolling by invitation

Zoonotic Influenza Surveillance in Belgium (ZOOIS)

Influenza, Human

Belgium
Osivax
Aepodia

Completed

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Influenza

Belgium
GlaxoSmithKline

Completed

Revaccination With Influenza Vaccine GSK1247446A

Influenza | Influenza, Human

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' FluLaval® TF

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults

Influenza

Belgium
Universiteit Antwerpen
Yakult Honsha Co., LTD

Completed

Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing Homes

Respiratory Tract Infections

Belgium
Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent

Completed

Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

Influenza

Belgium
Osivax
Centre for vaccinology (CEVAC), University of Ghent

Completed

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Influenza

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent, Belgium

Completed

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Visterra, Inc.

Completed

Influenza Challenge Study of VIS410 in Healthy Volunteers

Influenza

Belgium
Crucell Holland BV

Completed

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Influenza

Belgium
Novartis
Novartis Vaccines

Completed

A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age

Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Pfizer

Completed

Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)

Hepatitis C

Belgium
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

Hepatitis B

Belgium
Hookipa Biotech GmbH
Centre for Vaccinology Ghent - CEVAC

Completed

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Cytomegalovirus Infection

Belgium
GlaxoSmithKline

Completed

Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine

Infections, Cytomegalovirus

Belgium
GlaxoSmithKline

Completed

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Infections, Cytomegalovirus

Belgium
GlaxoSmithKline

Completed

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
Solvay Pharmaceuticals

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

Healthy Volunteers

Belgium
LiteVax BV
University Hospital, Ghent; HarmonyCR, Melle, Belgium

Recruiting

Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine (TETRALITE-Ib)

Vaccination Reaction

Belgium

3

Subscribe